Found: 31
Select item for more details and to access through your institution.
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 3, p. 413, doi. 10.3390/cells11030413
- By:
- Publication type:
- Article
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.563249
- By:
- Publication type:
- Article
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2018, v. 37, p. 1, doi. 10.1186/s13046-018-0741-3
- By:
- Publication type:
- Article
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2017, p. 1, doi. 10.1186/s13046-017-0653-7
- By:
- Publication type:
- Article
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 14, p. 5165, doi. 10.3390/ijms21145165
- By:
- Publication type:
- Article
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line.
- Published in:
- Oncogene, 2004, v. 23, n. 52, p. 8439, doi. 10.1038/sj.onc.1207847
- By:
- Publication type:
- Article
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the 'biological window therapy'.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 144, n. 1, p. 113, doi. 10.1007/s10549-014-2840-y
- By:
- Publication type:
- Article
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress.
- Published in:
- Journal of Physiology, 2006, v. 576, n. 2, p. 391, doi. 10.1113/jphysiol.2006.115006
- By:
- Publication type:
- Article
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-49484-4
- By:
- Publication type:
- Article
Physico-chemical characterization and biological evaluation of two fibroin materials.
- Published in:
- Journal of Tissue Engineering & Regenerative Medicine, 2014, v. 8, n. 11, p. 874, doi. 10.1002/term.1592
- By:
- Publication type:
- Article
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with <i>MET</i> Amplification.
- Published in:
- PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0078656
- By:
- Publication type:
- Article
TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells.
- Published in:
- 2009
- By:
- Publication type:
- Correction notice
TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells.
- Published in:
- EMBO Journal, 2009, v. 28, n. 6, p. 677, doi. 10.1038/emboj.2009.8
- By:
- Publication type:
- Article
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00179
- By:
- Publication type:
- Article
Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii Tachyzoites.
- Published in:
- Frontiers in Microbiology, 2018, p. 1, doi. 10.3389/fmicb.2018.00753
- By:
- Publication type:
- Article
Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: Role of glutamine and of cell shrinkage.
- Published in:
- Journal of Cellular Physiology, 2005, v. 204, n. 1, p. 155, doi. 10.1002/jcp.20272
- By:
- Publication type:
- Article
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.942341
- By:
- Publication type:
- Article
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5925, doi. 10.3390/cancers14235925
- By:
- Publication type:
- Article
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2793, doi. 10.3390/cancers13112793
- By:
- Publication type:
- Article
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
- Published in:
- Cancers, 2021, v. 13, n. 1, p. 6, doi. 10.3390/cancers13010006
- By:
- Publication type:
- Article
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 666, doi. 10.3390/cancers12030666
- By:
- Publication type:
- Article
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 141, n. 1, p. 67, doi. 10.1007/s10549-013-2668-x
- By:
- Publication type:
- Article
Synergistic activity of letrozole and sorafenib on breast cancer cells.
- Published in:
- Breast Cancer Research & Treatment, 2011, v. 124, n. 1, p. 79, doi. 10.1007/s10549-009-0714-5
- By:
- Publication type:
- Article
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 299, doi. 10.1007/s00280-013-2356-x
- By:
- Publication type:
- Article
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 12, p. 2776, doi. 10.3390/pharmaceutics15122776
- By:
- Publication type:
- Article
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1240-x
- By:
- Publication type:
- Article
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141795
- By:
- Publication type:
- Article
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 953, doi. 10.1007/s11523-023-01005-0
- By:
- Publication type:
- Article
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
- Published in:
- Molecular Cancer, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1476-4598-13-143
- By:
- Publication type:
- Article
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
- Published in:
- Molecular Cancer, 2012, v. 11, n. 1, p. 1, doi. 10.1186/1476-4598-11-91
- By:
- Publication type:
- Article